What You Need To Know Ahead of Prudential Financial’s Earnings Release
How did your country report this? Share your view in the comments.
Diverging Reports Breakdown
What to Expect From Gilead Sciences’ Q2 2025 Earnings Report
Gilead Sciences, Inc. (GILD) is a global biopharmaceutical leader committed to discovering, developing, and delivering transformative therapies for life-threatening diseases. The company is set to release its fiscal Q2 earnings results on Thursday, Aug. 14. Analysts expect Gilead to report a profit of $1.96 per share, down 2.5% from $2.01 per share in the year-ago quarter. GILD stock has delivered robust gains over the past year, surging 52.2%, outpacing the S&P 500’s ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund’s (XLV) 10.2% decline.
Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical leader committed to discovering, developing, and delivering transformative therapies for life-threatening diseases. The company, currently valued at a market cap of $134.7 billion, has established a strong presence across several critical therapeutic areas, including HIV, viral hepatitis, oncology, and inflammatory diseases.
Gilead has been a pioneer in antiviral research, particularly in the treatment and prevention of HIV/AIDS, where its therapies have significantly improved patient outcomes and quality of life. The company is set to release its fiscal Q2 earnings results on Thursday, Aug. 14. Ahead of the event, analysts expect GILD to report a profit of $1.96 per share, down 2.5% from $2.01 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three of the past four quarters, while missing in the recent quarter.
More News from Barchart
For the current year, analysts expect GILD to report EPS of $7.91, up 71.2% from $4.62 in fiscal 2024.
www.barchart.com
GILD stock has delivered robust gains over the past year, surging 52.2%, outpacing the S&P 500’s ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund’s (XLV) 10.2% decline over the same time frame.
www.barchart.com
On June 10, Gilead Sciences shares fell over 2% following negative news about one of its investigational HIV programs, contrasting with the S&P 500’s 0.6% gain. The FDA ordered Gilead to halt clinical trials of a two-drug HIV treatment (GS-1720 and GS-4182) due to observed low CD4+ T-cell counts in some participants. The drugs were being tested against Gilead’s current HIV therapy, Biktarvy.
The consensus opinion on GILD stock is fairly bullish, with an overall “Moderate Buy” rating. Among the 28 analysts covering the stock, 18 advise a “Strong Buy” rating, one “Moderate Buy,” and nine suggest “Hold.” GILD’s average analyst price target is $118.16, indicating a potential upside of 7.3% from the current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Here’s What to Expect From DoorDash’s Next Earnings Report
DoorDash is gearing up to announce its second-quarter results after the market closes on Wednesday, Aug. 6. The company develops technology to connect customers with merchants through an on-demand food delivery application. DASH stock prices have soared 129.5% over the past 52 weeks, significantly outperforming the S&P 500 Index’s 13.4% returns and the Consumer Discretionary Select Sector SPDR Fund’s 18.8% gains during the same time frame. Of the 37 analysts covering the stock, opinions include 23 “Strong Buys,” two “Moderate Buys” and 12 “Holds”
Valued at $101.9 billion by market cap, San Francisco, California-based DoorDash, Inc. (DASH) provides restaurant food delivery services. The company develops technology to connect customers with merchants through an on-demand food delivery application. DoorDash is gearing up to announce its second-quarter results after the market closes on Wednesday, Aug. 6.
Ahead of the event, analysts expect DASH to deliver a profit of $0.42 per share, marking a significant improvement from the loss of $0.38 per share reported in the year-ago quarter. While the company has surpassed Street’s bottom-line projections twice over the past four quarters, it has missed the estimates on two other occasions.
More News from Barchart
For the full fiscal 2025, analysts expect DoorDash to deliver an EPS of $2.16, significantly up from the $0.29 reported in fiscal 2024. In fiscal 2026, its earnings are expected to further surge 62.5% year-over-year to $3.51 per share.
www.barchart.com
DASH stock prices have soared 129.5% over the past 52 weeks, significantly outperforming the S&P 500 Index’s ($SPX) 13.4% returns and the Consumer Discretionary Select Sector SPDR Fund’s (XLY) 18.8% gains during the same time frame.
www.barchart.com
DoorDash’s stock prices plunged 7.4% in the trading session after the release of its mixed Q1 results on May 6. The company’s total orders jumped 18% year-over-year to 732 million, while its marketplace gross order value surged by 20% to $23.1 billion. Meanwhile, its revenues increased 20.7% year-over-year to $3 billion, but missed the Street’s expectations by 2.3%. Nevertheless, its EPS came in at $0.44, marking a notable improvement from $0.06 loss per share in the year-ago quarter, and surpassing the consensus estimates by 10%.
The consensus opinion on DASH stock is cautiously optimistic with a “Moderate Buy” rating overall. Of the 37 analysts covering the stock, opinions include 23 “Strong Buys,” two “Moderate Buys,” and 12 “Holds.” As of writing, the stock is trading slightly above its mean price target of $237.82.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Expedia’s Quarterly Earnings Preview: What You Need to Know
Expedia Group, Inc. (EXPE) is a Seattle-based travel technology company that connects global travelers with lodging, transportation, and activity providers. The travel titan is expected to announce its fiscal Q2 2025 earnings results after the market closes on Thursday, Aug. 7. Analysts expect the company to report a profit of $3.50 per share, up nearly 22.4% from $2.86 per share in the year-ago quarter. It has surpassed Wall Street’s earnings estimates in two of the last four quarters while missing on two other occasions.
With a market cap of $23.6 billion, Expedia Group, Inc. (EXPE) is a Seattle-based travel technology company that connects global travelers with lodging, transportation, and activity providers through an expansive portfolio of brands. The travel titan is expected to announce its fiscal Q2 2025 earnings results after the market closes on Thursday, Aug. 7.
Ahead of this event, analysts expect the company to report a profit of $3.50 per share, up nearly 22.4% from $2.86 per share in the year-ago quarter. It has surpassed Wall Street’s earnings estimates in two of the last four quarters while missing on two other occasions.
More News from Barchart
For fiscal 2025, analysts expect the company to report an EPS of $12.10, up 28.6% from $9.41 in fiscal 2024.
www.barchart.com
Shares of EXPE have gained 40.9% over the past 52 weeks, outperforming both the S&P 500 Index’s ($SPX) 13.4% rise and the Consumer Discretionary Select Sector SPDR Fund’s (XLY) 18.8% return over the period.
www.barchart.com
Expedia Group shares dropped 7.3% after the company released its Q1 2025 earnings on May 8. Revenue for the quarter grew 3.4% year-over-year to $3 billion, but fell short of Wall Street expectations amid weaker travel demand in the U.S. The company’s net loss deepened by 49% from the same period last year. Although adjusted EPS surged 90.5% year-over-year to $0.40, it still missed analyst estimates by 4.8%.
Analysts’ consensus view on Expedia’s stock is cautiously upbeat, with a “Moderate Buy” rating overall. Among 32 analysts covering the stock, 11 recommend “Strong Buy,” one suggests “Moderate Buy,” 19 indicate “Hold,” and the remaining analyst gives it a “Strong Sell.”
EXPE’s mean price target of $190.24 represents a marginal upswing from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Clorox Earnings Preview: What to Expect
The company is expected to release its Q4 results after the market closes on Thursday, Jul. 31. Analysts expect CLX to report an EPS of $2.24, up an impressive 23.1% from $1.82 reported in the year-ago quarter. The company has missed Street’s bottom-line estimates once over the past four quarters, it has surpassed the projections on three other occasions. Clorox stock prices dropped 2.4% in the trading session after the release of its disappointing Q3 results on May 5. As of writing, the stock is trading slightly below its mean price target of $134.69.
Oakland, California-based The Clorox Company (CLX) manufactures and markets consumer and professional products. It operates through Health and Wellness, Household, Lifestyle, and International segments. With a market cap of $15.6 billion, Clorox’s portfolio consists of diverse brands sold in more than 100 countries and nearly every region of the world.
The company is expected to release its Q4 results after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect CLX to report an EPS of $2.24, up an impressive 23.1% from $1.82 reported in the year-ago quarter. While the company has missed Street’s bottom-line estimates once over the past four quarters, it has surpassed the projections on three other occasions.
More News from Barchart
For the full fiscal 2025, its EPS is expected to come in at $7.08, marking a solid 14.8% growth from $6.17 in fiscal 2024. But in fiscal 2026, its earnings are expected to plunge 8.6% year-over-year to $6.47 per share.
www.barchart.com
CLX stock prices have dipped 2.4% over the past 52 weeks, notably underperforming the S&P 500 Index’s ($SPX) 13.4% returns and the Consumer Staples Select Sector SPDR Fund’s (XLP) 4.5% uptick during the same time frame.
www.barchart.com
CLX stock prices dropped 2.4% in the trading session after the release of its disappointing Q3 results on May 5. Due to an unfavorable price mix, the company’s organic sales dropped by 2% year-over-year. Further, its overall sales dropped 8.1% year-over-year to $1.7 billion due to divestitures of the VMS and Argentina businesses. This figure missed consensus estimates by a large margin. Moreover, its adjusted EPS plunged 15.2% year-over-year to $1.45, missing the consensus estimates by 7.6%, breaking its 10 quarters long streak of positive earnings surprises.
CLX stock maintains a consensus “Hold” rating overall, as analysts remain cautious about its prospects. Of the 18 analysts covering the stock, opinions include only one “Strong Buy,” 13 “Holds,” and four “Strong Sell” ratings. As of writing, the stock is trading slightly below its mean price target of $134.69.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
What You Need To Know Ahead of Prudential Financial’s Earnings Release
Prudential Financial, Inc. (PRU) provides insurance, investment management, and other financial products and services worldwide. With a market cap of $36.2 billion, Prudential operates through PGIM, Retirement Strategies, Group Insurance, Individual Life, and International Businesses segments. The insurance giant is expected to release its Q2 earnings after the market closes on Wednesday, Jul. 30. PRU has plunged 16.4% over the past 52 weeks, significantly underperforming the S&P 500 Index’s ($SPX) 13.4%.
New Jersey-based Prudential Financial, Inc. (PRU) provides insurance, investment management, and other financial products and services worldwide. With a market cap of $36.2 billion, Prudential operates through PGIM, Retirement Strategies, Group Insurance, Individual Life, and International Businesses segments.
The insurance giant is expected to release its Q2 earnings after the market closes on Wednesday, Jul. 30. Ahead of the event, analysts expect Prudential to report a profit of $3.24 per share, down 4.4% from $3.39 per share reported in the year-ago quarter. The company has missed Wall Street’s adjusted EPS projections twice over the past four quarters while exceeding the estimates on two other occasions.
More News from Barchart
For the full fiscal 2025, analysts expect PRU to deliver an EPS of $13.45, up 6.6% from $12.62 in fiscal 2024. In fiscal 2026, its earnings are expected to further grow 9.4% year-over-year to $14.72 per share.
www.barchart.com
PRU has plunged 16.4% over the past 52 weeks, significantly underperforming the S&P 500 Index’s ($SPX) 13.4% returns and the Financial Select Sector SPDR Fund’s (XLF) 22.3% surge during the same time frame.
www.barchart.com
Prudential Financial’s stock prices dipped nearly 1% in the trading session after the release of its mixed Q1 results on Apr. 30. While the company’s net investment income observed a significant improvement, its premiums observed a steep decline. Prudential’s overall revenues came in at $13.5 billion, missing the Street expectations by a high-single-digit figure. Meanwhile, its adjusted EPS for the quarter came in at $3.29, beating the consensus estimates by two cents.
PRU holds a consensus “Hold” rating overall as analysts remain cautious about the stock’s prospects. Of the 17 analysts covering the stock, only two recommend “Strong Buy,” while 13 suggest “Hold” and two advocate a “Strong Sell” rating. Its mean price target of $116.13 represents an 11.4% premium to current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com